C&L: Novo Nordisk promotes CMO

Novo Nordisk has promoted Dr. Alan C. Moses to chief medical officer, North America. In his new role, Dr. Moses will provide strategic input and oversight into the company's breakthrough diabetes and biopharmaceutical clinical research and medical affairs.

Pacgen Biopharmaceuticals has named Robert 'Duffy' DuFresne president and chief executive officer. DuFresne replaces Dr. David Cheng, who held the position since he co-founded the company in 2004.

Ricerca Biosciences has not renewed CEO Tom Bradshaw's contract. No reason was given.

Jean Pierre Tirouflet has joined BioSystems International as CEO. Tirouflet had been chairman and CEO of the French specialty chemicals company Rhodia.

Danish company Astion Pharma has appointed Lars Smedegaard Andersen as its new president and CEO.

t2cure has appointed Dr. Manfred Ruediger as CEO.

Zila announced that Lawrence A. Gyenes has been named CFO.

Cytochroma has named Dr. P. Martin Petkovich as full-time chief scientific officer.

RXi Pharmaceuticals announced that Pamela A. Pavco, Ph.D., has joined RXi as vice president of pharmaceutical development.

The New York Biotechnology Association has named Nathan Tinker as its executive director.

ITI Life Sciences has named Dr. Jim Greaves as director of marketing and communications.

Adventrx Pharmaceuticals has appointed Michele L. Yelmene to the new position of vice president of regulatory affairs.

Cardiome Pharma announced the retirement of the chairman of the company's board of directors, Dr. Mark C. Rogers.

TransPharma Medical has named Larry Ellberger to the board of directors.

SinoFresh HealthCare has appointed Raymond A. Zipprich, CPA, Thomas M. Fitzgerald, Esq., and Bruce W. Simpson to its board of directors.

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.